COIOSDeep risk insights through multi-disciplinary research across the globe
an aerial view of a city with snow on the roofs
Item confirms Peer-reviewed Added

Infant RSV hospitalisations fell two thirds in Quebec's first nirsevimab season

In Quebec's first season of offering nirsevimab to all infants, hospitalisations with a positive RSV test in those aged 0-5 months fell by 66%, and bronchiolitis emergency visits by 35%.

Quebec offered nirsevimab to every infant in the 2024-25 RSV season, and compared those aged 0-5 months with older children who were not eligible. Hospitalisations with a positive RSV test fell by 66%, and emergency visits for acute bronchiolitis by 35%. Between 323 and 746 hospitalisations were estimated to have been prevented over the season.

Why it is interesting: The fall is measured against older children who were not offered nirsevimab, so season strength is allowed for.

Source
Epidemiology, 15 September 2026
Paper
Impact of the first nirsevimab immunization campaign on infant RSV-related emergency department visits and hospitalizations in Québec, Canada
Authors
Bemmo A, Fortin É, Fortin P, Doggui R, Guay CA, Amini R et al.
DOI
10.1097/ede.0000000000002050
Type
Peer-reviewed article
Design
Population-level quasi-experimental evaluation (difference-in-differences and counterfactual) using surveillance and administrative data, all Québec children under 18, 2024-25 RSV season versus prior seasons
Verdict
Confirms prior evidence
Driver
Infection and pandemics

Other drivers in Behavioural science